Biogen said more data had become available after the two aducanumab studies were discontinued, resulting in a new analysis that showed one of the trials met the main goal. Photograph: Reuters

Biogen revived plans on Tuesday to seek US approval for Alzheimer’s treatment aducanumab, surprising investors and saying data from more patients in t(...)

Amgen said it expects the deal to produce tax benefits with a present cash value of $2.2 billion. Photograph: Getty Images

Amgen will buy Celgene’s psoriasis drug Otezla for $13.4 billion (€12.05 billion) in cash, clearing the way for Bristol-Myers Squibb to go ahead with (...)